Group 1 - The core point of the news is that Guangdong Taiankang Pharmaceutical Co., Ltd. has received approval for a Phase II clinical trial of CKBA cream for treating non-segmental vitiligo in children aged 2 to 12, marking a significant advancement in innovative treatments for pediatric vitiligo [1] - The clinical trial approval was granted by the National Medical Products Administration, allowing the company to conduct a multi-center, randomized, double-blind, placebo-controlled study to assess safety, efficacy, and pharmacokinetics [1] - Vitiligo is a chronic autoimmune disease affecting 0.5% to 2.0% of the global population, with children representing approximately 32% to 40% of total patients, highlighting a significant unmet clinical need for treatments specifically for this demographic [1] Group 2 - CKBA is a first-in-class immunomodulator targeting ACC1/MFE-2, which suppresses the differentiation of CD8+ T cells and downregulates the expression of IFN-γ and IL-17, thereby improving the immune environment of the skin and preventing the expansion of vitiligo [2] - The NB-UVB therapy activates melanocyte stem cells, promoting their differentiation into mature melanocytes to produce melanin, complementing the action of CKBA [2] - CKBA is derived from natural products and has been recognized for its innovative value and clinical potential, holding intellectual property rights in China, the United States, the European Union, and Japan [2]
泰恩康CKBA乳膏儿童白癜风Ⅱ期临床申请获批